NVO advances obesity pipeline with CagriSema and Amycretin while expanding through major deals amid rising competition.

Eli Lilly is a global healthcare giant, generating strong growth from a diverse portfolio of blockbuster medications. Viking ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Viking Therapeutics faces tough obesity drug rivals, with VK2735 showing promise but an uncertain edge. Find out why VKTX ...

With VKTX surging on clinical results and NVO investing to cement market share, investors face a high-stake GLP-1 showdown.

Wake up with Breakfast news in your inbox every market day. Sign Up For Free » Viking Therapeutics' leading candidate, VK2735, is a weight loss medicine. Many pharmaceutical giants are looking to ...

Investors looking to cash in on the fast-growing market for weight management medicines will naturally turn to the two ...

Viking Therapeutics' VENTURE-Oral study of VK2735 has completed enrollment, with a readout set for H2'25. The company's phase 3 program on subcutaneous VK2735 is getting underway, although given ...

The European company is a potential competitor because, similarly, Viking has gained a degree of fame with its VK2735, an investigational weight-loss treatment. The medicine performed exceedingly ...